Generation and purification of iPSC-derived cardiomyocytes for clinical applications
Abstract Background Over the past decade, the field of cell therapy has rapidly expanded with the aim to replace and repair damaged cells and/or tissue. Depending on the disease many different cell types can be used as part of such a therapy. Here we focused on the potential treatment of myocardial...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-025-04319-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850182024874164224 |
|---|---|
| author | M. Generali D. Kehl D. Meier D. Zorndt K. Atrott H. Saito MY. Emmert SP. Hoerstrup |
| author_facet | M. Generali D. Kehl D. Meier D. Zorndt K. Atrott H. Saito MY. Emmert SP. Hoerstrup |
| author_sort | M. Generali |
| collection | DOAJ |
| description | Abstract Background Over the past decade, the field of cell therapy has rapidly expanded with the aim to replace and repair damaged cells and/or tissue. Depending on the disease many different cell types can be used as part of such a therapy. Here we focused on the potential treatment of myocardial infarction, where currently available treatment options are not able to regenerate the loss of healthy heart tissue. Method We generated good manufacturing practice (GMP)-compatible cardiomyocytes (iCMs) from transgene- and xenofree induced pluripotent stem cells (iPSCs) that can be seamless adapted for clinical applications. Further protocols were established for replating and freezing/thawing iCMs under xenofree conditions. Results iCMs showed a cardiac phenotype, with the expression of specific cardiac markers and absence of pluripotency markers at RNA and protein level. To ensure a pure iCMs population for in vivo applications, we minimized risks of iPSC contamination using RNA-switch technology to ensure safety. Conclusion We describe the generation and further processing of xeno- and transgene-free iCMs. The use of GMP-compliant differentiation protocols ab initio facilitates the clinical translation of this project in later stages. |
| format | Article |
| id | doaj-art-1866aaf9ce414ae9b012da804c853e44 |
| institution | OA Journals |
| issn | 1757-6512 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj-art-1866aaf9ce414ae9b012da804c853e442025-08-20T02:17:46ZengBMCStem Cell Research & Therapy1757-65122025-04-0116111210.1186/s13287-025-04319-0Generation and purification of iPSC-derived cardiomyocytes for clinical applicationsM. Generali0D. Kehl1D. Meier2D. Zorndt3K. Atrott4H. Saito5MY. Emmert6SP. Hoerstrup7Institute for Regenerative Medicine, University of ZurichInstitute for Regenerative Medicine, University of ZurichInstitute for Regenerative Medicine, University of ZurichInstitute for Regenerative Medicine, University of ZurichCenter for Surgical Research, University of Zurich, University Hospital ZurichDepartment of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto UniversityInstitute for Regenerative Medicine, University of ZurichInstitute for Regenerative Medicine, University of ZurichAbstract Background Over the past decade, the field of cell therapy has rapidly expanded with the aim to replace and repair damaged cells and/or tissue. Depending on the disease many different cell types can be used as part of such a therapy. Here we focused on the potential treatment of myocardial infarction, where currently available treatment options are not able to regenerate the loss of healthy heart tissue. Method We generated good manufacturing practice (GMP)-compatible cardiomyocytes (iCMs) from transgene- and xenofree induced pluripotent stem cells (iPSCs) that can be seamless adapted for clinical applications. Further protocols were established for replating and freezing/thawing iCMs under xenofree conditions. Results iCMs showed a cardiac phenotype, with the expression of specific cardiac markers and absence of pluripotency markers at RNA and protein level. To ensure a pure iCMs population for in vivo applications, we minimized risks of iPSC contamination using RNA-switch technology to ensure safety. Conclusion We describe the generation and further processing of xeno- and transgene-free iCMs. The use of GMP-compliant differentiation protocols ab initio facilitates the clinical translation of this project in later stages.https://doi.org/10.1186/s13287-025-04319-0Induced pluripotent stem cellsCardiomyocytesCell therapyClinical translation |
| spellingShingle | M. Generali D. Kehl D. Meier D. Zorndt K. Atrott H. Saito MY. Emmert SP. Hoerstrup Generation and purification of iPSC-derived cardiomyocytes for clinical applications Stem Cell Research & Therapy Induced pluripotent stem cells Cardiomyocytes Cell therapy Clinical translation |
| title | Generation and purification of iPSC-derived cardiomyocytes for clinical applications |
| title_full | Generation and purification of iPSC-derived cardiomyocytes for clinical applications |
| title_fullStr | Generation and purification of iPSC-derived cardiomyocytes for clinical applications |
| title_full_unstemmed | Generation and purification of iPSC-derived cardiomyocytes for clinical applications |
| title_short | Generation and purification of iPSC-derived cardiomyocytes for clinical applications |
| title_sort | generation and purification of ipsc derived cardiomyocytes for clinical applications |
| topic | Induced pluripotent stem cells Cardiomyocytes Cell therapy Clinical translation |
| url | https://doi.org/10.1186/s13287-025-04319-0 |
| work_keys_str_mv | AT mgenerali generationandpurificationofipscderivedcardiomyocytesforclinicalapplications AT dkehl generationandpurificationofipscderivedcardiomyocytesforclinicalapplications AT dmeier generationandpurificationofipscderivedcardiomyocytesforclinicalapplications AT dzorndt generationandpurificationofipscderivedcardiomyocytesforclinicalapplications AT katrott generationandpurificationofipscderivedcardiomyocytesforclinicalapplications AT hsaito generationandpurificationofipscderivedcardiomyocytesforclinicalapplications AT myemmert generationandpurificationofipscderivedcardiomyocytesforclinicalapplications AT sphoerstrup generationandpurificationofipscderivedcardiomyocytesforclinicalapplications |